益佰制药(600594) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥545,648,893.87, representing a decrease of 16.97% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was -¥62,657,845.21, a decline of 249.31% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was -¥68,092,758.30, down 275.13% from the previous year[2]. - The net profit for the third quarter of 2024 was -174,241,819.86 CNY, compared to a net profit of 161,499,907.31 CNY in the same period of 2023, indicating a significant decline[18]. - The total profit margin for the third quarter of 2024 was significantly impacted, with a total profit of -173,766,399.26 CNY compared to a profit of 194,907,546.17 CNY in the same period of 2023[18]. - Total operating revenue for the first three quarters of 2024 was CNY 1,713,840,317.37, a decrease of 19.7% compared to CNY 2,136,834,252.04 in the same period of 2023[17]. - The company's net profit attributable to shareholders decreased significantly, with undistributed profits dropping to CNY 902,047,094.34 from CNY 1,123,465,581.46, a decline of 19.7%[15]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥4,167,157,491.04, a decrease of 9.36% compared to the end of the previous year[4]. - Total assets decreased to CNY 4,167,157,491.04 in Q3 2024 from CNY 4,597,253,863.18 in Q3 2023, a reduction of 9.3%[15]. - Total liabilities decreased to CNY 1,390,381,859.05 in Q3 2024 from CNY 1,578,998,904.30 in Q3 2023, a decline of 11.9%[15]. - The company reported a decrease in short-term borrowings to CNY 290,825,916.68 from CNY 446,045,418.03, a reduction of 34.8%[15]. - The total equity attributable to shareholders at the end of Q3 2024 was ¥2,648,055,698.32, a decrease of 8.20% from the previous year[4]. Cash Flow and Expenses - The cash flow from operating activities for the year-to-date was ¥199,803,322.61, down 41.77% compared to the previous year[4]. - The cash flow from operating activities for the third quarter of 2024 was 199,803,322.61 CNY, compared to 343,155,292.85 CNY in the same quarter of 2023, reflecting a decline of about 41.8%[22]. - The company incurred operating expenses of 1,867,618,947.16 CNY in the third quarter of 2024, compared to 2,002,763,789.31 CNY in the same quarter of 2023, showing a reduction in expenses[22]. - The cash flow from investing activities for the third quarter of 2024 was -56,385,904.48 CNY, compared to -102,439,355.09 CNY in the same quarter of 2023, indicating an improvement in cash outflow[22]. - The company raised 380,000,000.00 CNY through financing activities in the third quarter of 2024, down from 530,000,000.00 CNY in the same quarter of 2023[22]. Share Repurchase - The company plans to repurchase shares with a total amount between RMB 20 million and RMB 40 million, with a maximum repurchase price set at RMB 8.58 per share[12]. - As of September 30, 2024, the company has repurchased a total of 5,037,400 shares, accounting for 0.64% of the total share capital[12]. - The highest repurchase price recorded was RMB 3.06 per share, while the lowest was RMB 2.89 per share[12]. - The total amount paid for share repurchases reached RMB 14,997,308, excluding transaction fees[12]. - The company held a board meeting on November 29, 2023, to approve the share repurchase plan[12]. Current Assets - As of September 30, 2024, the total current assets decreased to RMB 1,732,617,097.29 from RMB 2,069,148,018.19 at the end of 2023, representing a decline of approximately 16.2%[13]. - Cash and cash equivalents amounted to RMB 619,878,982.72, down from RMB 699,468,723.75, indicating a decrease of about 11.4%[13]. - Accounts receivable increased to RMB 239,754,999.02 from RMB 227,055,742.82, reflecting an increase of approximately 5.9%[13]. - Inventory decreased to RMB 552,834,263.39 from RMB 586,650,795.70, showing a decline of about 5.8%[13]. - The cash and cash equivalents at the end of the third quarter of 2024 were 607,876,290.72 CNY, down from 683,933,062.18 CNY at the end of the third quarter of 2023, a decrease of approximately 11.1%[23]. Research and Development - Research and development expenses increased to CNY 79,177,945.47 in 2024 from CNY 73,852,804.23 in 2023, representing a growth of 7.1%[17]. Future Plans - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming quarters[16].